Reproductive health

CCRM Fertility Announces New Location Serving The Woodlands, Texas

Retrieved on: 
Monday, January 9, 2023
Gynaecology, Fertility, Endometriosis, Infertility, The Woodlands, CST, Fertility preservation, Baylor College of Medicine, Research, Obstetrics, Science, Suite, Patient, University, Polycystic ovary syndrome, Baylor University, Physician, Parent, Reproductive health, Medical device, Houstonian, Greater Houston

HOUSTON, Jan. 9, 2023 /PRNewswire/ -- CCRM Fertility, the global pioneer in fertility treatment, research and science, today announced the expansion of its Greater Houston network with the opening of a new satellite office in The Woodlands, Texas. Led by reproductive endocrinology and infertility specialist Dr. Beth Zhou, The Woodlands office was created to better serve the area's growing need for high-quality fertility treatments. CCRM Fertility currently has four locations and five reproductive endocrinology and infertility specialists serving the Greater Houston area.

Key Points: 
  • HOUSTON, Jan. 9, 2023 /PRNewswire/ -- CCRM Fertility , the global pioneer in fertility treatment, research and science, today announced the expansion of its Greater Houston network with the opening of a new satellite office in The Woodlands, Texas.
  • Led by reproductive endocrinology and infertility specialist Dr. Beth Zhou , The Woodlands office was created to better serve the area's growing need for high-quality fertility treatments.
  • CCRM Fertility currently has four locations and five reproductive endocrinology and infertility specialists serving the Greater Houston area.
  • "Our newest satellite office in The Woodlands is an exciting expansion to help even more Texans start or grow their families," said CCRM Fertility CEO Bob LaGalia.

Femasys Inc. Announces Commercial Availability of its FemCath Intrauterine Device

Retrieved on: 
Monday, December 19, 2022
Woman, Reproductive health, Infertility, FDA, Birth control

ATLANTA, Dec. 19, 2022 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a biomedical company aiming to meet women's needs worldwide by developing a suite of product candidates that include minimally invasive, in-office technologies for reproductive health, today announced that its product, FemCath™, the first FDA-cleared intrauterine catheter for selective tubal evaluation, is now commercially available. FemCath is used in conjunction with Femasys’ FemVue device for an ultrasound-based diagnostic test as part of an infertility evaluation, which is essential prior to any infertility treatment, including with Femasys’ other biomedical solution in development, FemaSeed®.

Key Points: 
  • FemCath is used in conjunction with Femasys’ FemVue device for an ultrasound-based diagnostic test as part of an infertility evaluation, which is essential prior to any infertility treatment, including with Femasys’ other biomedical solution in development, FemaSeed®.
  • FemCath utilizes Femasys’ proprietary delivery platform, which involves placement of balloon technology close to the opening of a selected fallopian tube for directed delivery.
  • Femasys’ other biomedical solutions in development, FemaSeed® and FemBloc®, utilize the same delivery platform for directed delivery of other materials.
  • In the meantime, FemCath will provide another measure of incremental revenue for Femasys when used with FemVue for any conditions requiring tubal evaluation.”

OB-GYN Mary Jane Minkin, M.D., Shares Considerations for Women’s Health Resolutions in 2023

Retrieved on: 
Thursday, January 5, 2023
Mental Health, General Health, Family, Fitness & Nutrition, Consumer, Other Retail, Vitamins, Supplements, Supermarket, Health, Retail, Other Health, Other Consumer, Teens, Women, Children, Online Retail, Baby, Maternity, Luteinizing hormone, Gynaecology, Mental health, Ovulation, Anxiety, Menopause, Pain, Make, Vulva, Fertility, Smoking, Multivitamin, Water, Vitamin, Depression, Sleep, Woman, Vegetable, LH, Pregnancy, HCP, Yale School of Medicine, Birth, Reproductive Sciences, Moisturizer, Nutrient, Exercise, Diet, Health, PH, Reflexive pronoun, Vagina, Vaginal lubrication, Ageing, Habit, Dry, Menstrual cycle, Reproductive health, Medicine, Birth control, Obstetrics, Lactobacillus

Top considerations for resolutions often involve improving one’s health, such as sticking to a fitness routine or committing to a proper diet.

Key Points: 
  • Top considerations for resolutions often involve improving one’s health, such as sticking to a fitness routine or committing to a proper diet.
  • "Making goals for the new year is a great way to re-evaluate one’s health routines," says Dr. Minkin.
  • “I encourage women to consider all the different changes – large or small – that they can make to improve their health and wellbeing from vaginal, sexual and reproductive health to mental health."
  • Dr. Minkin offers the following considerations for women’s health resolutions in the new year.

Intrauterine Insemination (IUI) Success can be Predicted with a New IUI Assessment Released by Posterity Health and Path Fertility

Retrieved on: 
Wednesday, January 4, 2023
Family, Health, Consumer, Baby, Maternity, General Health, Men, Semen analysis, Education, IVF, Infertility, OBGYN, Conception, Female, Male, Fertility, Health, Excellent, Semen, Pregnancy, Patient, Reis, Entrepreneurship, Poverty, REI, IUI, Live birth, Reproductive health, Birth control

Together the companies offer a new comprehensive IUI Assessment that evaluates multiple semen parameters and predicts the likelihood of success with intrauterine insemination (IUI).

Key Points: 
  • Together the companies offer a new comprehensive IUI Assessment that evaluates multiple semen parameters and predicts the likelihood of success with intrauterine insemination (IUI).
  • By combining the two tests Posterity Health and Path Fertility provide the most complete and cutting-edge assessment of male reproductive health.
  • “The studies to date show that the integrated IUI Assessment is highly predictive of pregnancy outcomes with IUI.
  • Couples who complete the IUI Assessment earlier in the conception journey will benefit emotionally and financially by understanding the likelihood of IUI success.

Children's Home Society of North Carolina Introduces New Sexual Health Education Program Statewide For Teens in Out-of-Home Care

Retrieved on: 
Wednesday, January 4, 2023
FREE, STI, Child, Family, Education, Health education, Tennessee Children's Home Society, Life, Reproductive health, CHS, Multimedia, Prevalence, SYNC, Pregnancy, Birth control, Residential care

Youth in out-of-home care have higher rates of pregnancy, STIs, and associated sexual risk behaviors than youth living with their families.

Key Points: 
  • Youth in out-of-home care have higher rates of pregnancy, STIs, and associated sexual risk behaviors than youth living with their families.
  • "SYNC provides us with the effective, research-based prevention strategies to improve the sexual reproductive health of these youth."
  • Children's Home Society offers a network of services and support throughout North Carolina to help establish and sustain healthy, loving relationships in every family.
  • For 120 years, Children's Home Society has provided a broad spectrum of programs and services including adoption, foster care, parenting education, family preservation, and youth responsibility.

OTC Markets Group Grants Evofem Additional Time to File Quarterly Report on Form 10-Q for the Quarter Ended September 30, 2022

Retrieved on: 
Thursday, December 29, 2022
FDA, OTCQB, Reproductive health, OTC Markets Group, SAN, Pregnancy, Citric acid, Lactic acid, Birth control

SAN DIEGO, Dec. 29, 2022 /PRNewswire/ -- Evofem Biosciences, Inc. (OTCQB: EVFM) today announced that it has been granted additional time by the OTC Markets Group to file its Quarterly Report on Form 10-Q for the quarter ended September 30, 2022 (the "10-Q").

Key Points: 
  • SAN DIEGO, Dec. 29, 2022 /PRNewswire/ -- Evofem Biosciences, Inc. (OTCQB: EVFM) today announced that it has been granted additional time by the OTC Markets Group to file its Quarterly Report on Form 10-Q for the quarter ended September 30, 2022 (the "10-Q").
  • Previously, the OTC Markets Group provided until December 29, 2022 to file the 10-Q .
  • Evofem Biosciences, Inc., is developing and commercializing innovative products to address unmet needs in women's sexual and reproductive health.
  • Phexxi® is a registered trademark of Evofem Biosciences, Inc.
    Phexxi is an on-demand method of birth control used to prevent pregnancy.

Illumina To Webcast Upcoming Investor Conference

Retrieved on: 
Monday, December 19, 2022
Genome, Reproductive health, Health, Agriculture, DNA, Research, Illumina, Inc., Webcast, SAN, Conference, Illumina

SAN DIEGO, Dec. 19, 2022 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced that its executives will be speaking at the following investor conference:

Key Points: 
  • SAN DIEGO, Dec. 19, 2022 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced that its executives will be speaking at the following investor conference:
    41st Annual J.P. Morgan Healthcare Conference on January 9, 2023
    The webcast can be accessed through the Investor Info section of Illumina's website at investor.illumina.com .
  • A replay will be posted on Illumina's website after the event and will be available for at least 30 days following.
  • Illumina is improving human health by unlocking the power of the genome.
  • Our products are used for applications in the life sciences, oncology, reproductive health, agriculture and other emerging segments.

Femasys Inc. Reports Encouraging Promotional Launch of FemCerv at AAGL Based on Positive Reception by Gynecologic Physicians and Surgeons

Retrieved on: 
Monday, December 12, 2022
Tubing (recreation), Reproductive health, Woman, Surgeon, Annual report, AAGL, FDA, Anesthesia, Safety, Insemination, Risk, Research, Cervical cancer, Infertility, Gynaecology, Birth control, Medical imaging

ATLANTA, Dec. 12, 2022 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a biomedical company aiming to meet women's needs worldwide by developing a suite of product candidates that include minimally invasive, in-office technologies for reproductive health, today reported that it held a promotional launch of its diagnostic product, FemCerv®, the first endocervical tissue sampler designed to improve tissue quality and quantity at the annual meeting of AAGL (formerly known as the meeting of the American Association for Gynecologic Laparoscopists), where the product was very well received by gynecologic physicians and surgeons. The annual AAGL meeting gathers laparoscopic surgeons worldwide dedicated to the research and advancement of minimally invasive gynecologic procedures.

Key Points: 
  • The annual AAGL meeting gathers laparoscopic surgeons worldwide dedicated to the research and advancement of minimally invasive gynecologic procedures.
  • “Gynecologic specialists acknowledged the novelty of FemCerv, an endocervical curette that obtains a virtually pain free comprehensive tissue sample when evaluating for cervical cancer.
  • FemVue works in conjunction with our other approved product, FemCath™, a selective catheter, which is expected to be commercially available later this month.
  • FemCerv is the first FDA-cleared product designed to capture a complete and uncontaminated endocervical tissue sample in a relatively pain-free procedure.

16 Days of Activism: Combatting Gender-based Violence is Essential for HIV Response

Retrieved on: 
Friday, December 9, 2022
Advocacy Group Opinion, Women, Teens, Children, Social Services, Social Activism, Consumer, Foundation, Professional Services, Philanthropy, DEI (Diversity, Equity and Inclusion), Public Policy, Government, AIDS, COVID-19, Health, Communications, Primary, Secondary, Education, Health minister, Negotiation, HIV, Policy, AIDS Healthcare Foundation, African Union, Woman, Safety and Opportunity for Girls Act, Union, Reproductive health, Society, Prevalence, Reproduction, AIDS, HIV/AIDS, School-related gender-based violence, PEP, GBV, Post-exposure prophylaxis, AHF, Comprehensive, COVID-19, UN Women, Marketing, UNAIDS, Multimedia, UN, Violence, Risk, Drug, Birth control, Sex (disambiguation), Activism

A recent joint policy paper by the African Union and UN Women reveals that an estimated one-in-three women will experience violence in their lifetimes.

Key Points: 
  • A recent joint policy paper by the African Union and UN Women reveals that an estimated one-in-three women will experience violence in their lifetimes.
  • Additionally, during the COVID-19 pandemic, many countries with reporting systems saw a 25% upsurge in cases of violence against women.
  • According to a UNAIDS report , violence prevents women from accessing lifesaving services, negotiating condom use, disclosing their HIV status, and achieving better treatment outcomes.
  • Additionally, intimate partner violence puts women at a 50% greater risk of contracting HIV - particularly in countries with high HIV prevalence.

Will Ventures and Founder Collective Team up with Three-Time NBA All-Star, Bradley Beal to Lead the National Cycling League (NCL) Seed Round

Retrieved on: 
Thursday, December 15, 2022
Reproductive health, NBA, Genetics, Atlanta Falcons, Tennessee Titans, Triple accreditation, MIT, Fast Lane Ventures, Los Angeles Chargers, Washington Wizards, NFL, DE, Invitae, City, Human, Celebrity, Woman, Entrepreneurship, NCL, Multimedia, General partnership, Harvard Business School, Fox Sports 1, LabCorp, Health, African Americans, National Basketball Players Association, Sport, Fertility, Entertainment, Los Angeles Rams

MIAMI, Dec. 15, 2022 /PRNewswire/ -- The National Cycling League (NCL), the first of its kind professional sports league powered by a groundbreaking technology platform, announced today that it closed its $7.5 million Seed financing.  This oversubscribed round was led by Will Ventures and included but not limited to Founder Collective, Collab Capital, Impellent Ventures, Bradley Beal (Washington Wizards), Jalen Ramsey (Los Angeles Rams), Derwin James (Los Angeles Chargers), Kevin Byard (Tennessee Titans), Casey Hayward (Atlanta Falcons), Michele Roberts

Key Points: 
  • Revolutionizing Professional Cycling in the U.S., the NCL Raises $7.5M in Seed Financing Largest Private Investment Ever in U.S. Professional Cycling.
  • MIAMI, Dec. 15, 2022 /PRNewswire/ --The National Cycling League (NCL), the first of its kind professional sports league powered by a groundbreaking technology platform, announced today that it closed its $7.5 million Seed financing.
  • "We also fully recognize the importance, power and necessity of a majority-minority and female-owned sports league."
  • "Building a new sports league from scratch is among the most ambitious entrepreneurial projects possible," says Eric Paley, General Partner at Founder Collective.